No buyout for Uniqure
But a licensing deal with CSL could have underappreciated benefits, even if expectations were for something much bigger.
Setback lays bare Novo’s need in haemophilia
Novo Nordisk is in danger of being left behind in haemophilia, and new safety fears around its lead R&D project make this more likely. But could a setback prompt deal…
Coronavirus stock hype proves infectious
Coronavirus-focused investors have willingly backed bona fide development and egregious publicity stunts alike.
The big cap empire strikes back
If the first three quarters of 2019 were dominated by pricing fears, the last saw a remarkable comeback for biopharma.
Novartis cast-off gives Pharming a gap-filler
Pharming picks up Novartis’s late-stage PI3K inhibitor and plans to launch it for an ultra-rare disease. How will the competition respond?
